Comparative Pharmacology
Head-to-head clinical analysis: DYLOJECT versus TOLMETIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYLOJECT versus TOLMETIN SODIUM.
DYLOJECT vs TOLMETIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It has anti-inflammatory, analgesic, and antipyretic effects.
50 mg intramuscularly every 6 hours as needed for pain; maximum 150 mg per day.
400 mg orally three times daily; maximum 1800 mg/day.
None Documented
None Documented
2-4 hours (terminal) in adults; prolonged in elderly (up to 6-8 hours) and hepatic impairment (up to 12 hours).
Terminal elimination half-life is approximately 4.5–6 hours (mean 5 hours); may be prolonged in elderly or patients with renal impairment
Renal: ~50% as unchanged drug and metabolites (glucuronide conjugates); Biliary/fecal: ~40% as metabolites; <5% unchanged in feces.
Renal excretion (~90% as unchanged drug and conjugates), with fecal excretion (~10% as metabolites)
Category C
Category D/X
NSAID
NSAID